Pharmacological study
( DrugBank: - / KEGG DRUG: - )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 28 | Systemic amyloidosis | 4 |
| 34 | Neurofibromatosis | 3 |
| 62 | Paroxysmal nocturnal hemoglobinuria | 1 |
| 74 | Prolactin secreting pituitary adenoma | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 89 | Lymphangioleiomyomatosis | 1 |
| 232 | Carney complex | 1 |
| 331 | Idiopathic multicentric castleman disease | 1 |
28. Systemic amyloidosis
Clinical trials : 335 / Drugs : 274 - (DrugBank : 86) / Drug target genes : 47 - Drug target pathways : 165
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
34. Neurofibromatosis
Clinical trials : 165 / Drugs : 189 - (DrugBank : 83) / Drug target genes : 93 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
62. Paroxysmal nocturnal hemoglobinuria
Clinical trials : 358 / Drugs : 160 - (DrugBank : 35) / Drug target genes : 33 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
74. Prolactin secreting pituitary adenoma
Clinical trials : 21 / Drugs : 31 - (DrugBank : 11) / Drug target genes : 16 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
89. Lymphangioleiomyomatosis
Clinical trials : 44 / Drugs : 44 - (DrugBank : 20) / Drug target genes : 27 - Drug target pathways : 138
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
232. Carney complex
Clinical trials : 2 / Drugs : 4 - (DrugBank : 1) / Drug target gene : 1 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
331. Idiopathic multicentric castleman disease
Clinical trials : 40 / Drugs : 45 - (DrugBank : 29) / Drug target genes : 43 - Drug target pathways : 163
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|